Humana Inc. (HUM) Price Target Cut to $217.00 by Analysts at Royal Bank Of Canada
Humana Inc. (NYSE:HUM) had its target price dropped by equities researchers at Royal Bank Of Canada from $222.00 to $217.00 in a report released on Thursday. The brokerage currently has a “sector perform” rating on the insurance provider’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 28.83% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $197.00 price objective for the company in a research note on Monday, July 25th. Jefferies Group restated a “buy” rating and issued a $220.00 price objective (up from $210.00) on shares of Humana in a research note on Monday, July 25th. RBC Capital Markets restated a “buy” rating and issued a $224.00 price objective (up from $220.00) on shares of Humana in a research note on Friday, July 22nd. Cantor Fitzgerald restated a “buy” rating on shares of Humana in a research note on Saturday, July 9th. Finally, Evercore ISI initiated coverage on shares of Humana in a research note on Thursday, September 22nd. They issued a “buy” rating and a $200.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $200.50.
Humana (NYSE:HUM) opened at 168.44 on Thursday. The firm has a market capitalization of $25.11 billion, a price-to-earnings ratio of 25.88 and a beta of 0.90. The stock has a 50 day moving average of $176.40 and a 200 day moving average of $175.87. Humana has a 12-month low of $150.00 and a 12-month high of $191.65.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/humana-inc-hum-price-target-cut-to-217-00-by-analysts-at-royal-bank-of-canada.html
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.23 by $0.07. Humana had a net margin of 1.76% and a return on equity of 11.11%. The business earned $14 billion during the quarter, compared to analysts’ expectations of $13.59 billion. During the same period in the previous year, the company earned $1.67 earnings per share. Humana’s revenue for the quarter was up 2.0% on a year-over-year basis. Equities research analysts anticipate that Humana will post $9.24 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Thursday, October 13th will be issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend is Tuesday, October 11th. Humana’s dividend payout ratio is currently 18.18%.
A number of large investors have recently modified their holdings of the company. Capstone Asset Management Co. raised its stake in shares of Humana by 0.9% in the third quarter. Capstone Asset Management Co. now owns 13,373 shares of the insurance provider’s stock worth $2,366,000 after buying an additional 124 shares in the last quarter. Creative Planning raised its stake in shares of Humana by 9.4% in the third quarter. Creative Planning now owns 7,174 shares of the insurance provider’s stock worth $1,269,000 after buying an additional 619 shares in the last quarter. Daiwa SB Investments Ltd. raised its stake in shares of Humana by 1.4% in the third quarter. Daiwa SB Investments Ltd. now owns 730 shares of the insurance provider’s stock worth $129,000 after buying an additional 10 shares in the last quarter. Fulton Bank N.A. bought a new stake in shares of Humana during the third quarter worth approximately $229,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Humana by 86.3% in the third quarter. BNP Paribas Arbitrage SA now owns 20,317 shares of the insurance provider’s stock worth $3,594,000 after buying an additional 9,414 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.